Clarity Pharmaceuticals Ltd (ASX:CU6)

Australia flag Australia · Delayed Price · Currency is AUD
3.390
-0.220 (-6.09%)
At close: Mar 2, 2026
-4.78%
Market Cap 1.26B
Revenue (ttm) 10.58M
Net Income (ttm) -96.35M
Shares Out 372.03M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,023,969
Average Volume 2,347,587
Open 3.460
Previous Close 3.610
Day's Range 3.260 - 3.460
52-Week Range 1.430 - 5.870
Beta 1.24
RSI 49.69
Earnings Date Feb 26, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 69
Stock Exchange Australian Securities Exchange
Ticker Symbol CU6
Full Company Profile

Financial Performance

In fiscal year 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.

Financial Statements

News

There is no news available yet.